Profit Opportunity Ondansetron Tab 4 mg and 8 mg 50
On behalf of pharmacy we wish to extend our sincere thanks for Rex Medical for the continued support of New Zealand pharmacy.
There is to be a brand change from Onrex-Rex to Ondansetron-Apo with the Sole Supply change to occur 1 August 2017.
The opportunity for pharmacy is to continue to support Onrex Tab both 4 mg and 8 mg through until you need to change during July 2017 or while stocks remain available.
Rex Medical has provided Price Support effective from 1 March 2017 which will enable pharmacy to make significant margin improvement for the period from 1 March 2017 to 30 April 2017. This is as stated significant and therefore we encourage you all to continue to support the incumbent brand until Sole Supply commences for the new product or stocks are exhausted, whichever comes first. This is then a WIN –WIN for both parties.
Note we are showing margin improvement only.
Onrex Tab 4 mg 50 –subsidy is $5.51 until 1 May 2017 when it will match the reference pricing at $3.36. The opportunity is for your margin to increase during the period from 1 March 2017 to 30 April 2017 from $0.1653 to $2.3153
Onrex Tab 8 mg 50 – subsidy is $6.19 until 1 May 2017 when it will match the reference pricing at $4.77. The opportunity is for your margin to increase during the period from 1 March 2017 to 30 April 2017 from $0.1857 to $1.6057
Hence the reason for us seeking your continue use of Onrex as per above explanation.
Also note that at the time of reference pricing the margins will adjust to $0.1008 for the 4 mg and $0.1431 for the 8 mg for both brands, one of which, will be a Low Cost Medicine with ProPharma.
Thank you in anticipation of your ongoing support and rest assured ProPharma will implement an automatic replacement once existing stocks are exhausted or 1 August 2017, whichever comes first.